The enhanced expression of CD30 (therapeutic target in CTCL) was especially observed in PB2B and Mac2A cells as these were harvested from a known CD30+ LPD patient. This evidence concerns the gene TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma.